Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chantix in JAMA

This article was originally published in The Tan Sheet

Executive Summary

Pfizer's prescription therapy Chantix (varenicline) was "significantly more efficacious" for smoking cessation after 12- and 24-week periods than GlaxoSmithKline's Zyban (bupropion SR), according to a study published in the July 5 issue of the Journal of the American Medical Association. David Gonzales, PhD, Oregon Health & Science University, et al., randomized 1,025 healthy smokers 18 to 75 years old, with fewer than three months smoking abstinence. The groups were treated with one of the two drugs or placebo and took exhaled carbon monoxide tests to confirm abstinence. For weeks 9-12, 44% of the Chantix group stayed abstinent compared to 17.7% for the placebo group and 29.5% for the Zyban group. Chantix received approval in May (1"The Tan Sheet" May 15, 2005, In Brief)...

Related Content

Rx smoking cessation pill





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts